Clinical pharmacology of intraperitoneal cisplatin-Reference-Cited by-同舟云学术

Clinical pharmacology of intraperitoneal cisplatin

Published:1985-01 Issue:1 Volume:20 Page:1-9
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Lopez Jose A.,Krikorian John G.,Reich Steven D.,Smyth Robert D.,Lee Francis H.,Issell Brian F.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference24 articles.

1. The role of cis-platinum in solid tumor therapy;Einhorn;New Engl. J. Med.,1979

2. Chemotherapy for stage III–IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), Adriamycin and cyclophosphamide: A preliminary report;Ehrlich;Cancer Treat Rep.,1979

3. Improved chemotherapy for ovarian cancer with cis-dichlorodiammineplatinum and Adriamycin;Bruckner;Cancer,1981

4. Management of ovarian carcinoma: Current concepts and future progress;Tobias;N. Engl. J. Med.,1976

5. Advanced ovarian cancer: Brief intensive combination chemotherapy and second look operation;Greco;Obstet. Gynecol.,1981

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer;Current Treatment Options in Oncology;2024-01-04

2. Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer;Cancer Chemotherapy and Pharmacology;2023-03

3. Current State of Pleural-Directed Adjuncts Against Malignant Pleural Mesothelioma;Frontiers in Oncology;2022-05-02

4. Effect of neoadjuvant chemotherapy combined with intraperitoneal chemotherapy after interval tumor cell reduction on the prognosis of advanced epithelial ovarian cancer;European Journal of Gynaecological Oncology;2022

5. Landmark Trials in the Surgical Management of Mesothelioma;Annals of Surgical Oncology;2021-01-31